The applicant has reported that a tumor suppressor gene (p53) complexed to liposomes attenuates the growth of a malignant human breast tumor. In these studies, nude mice, inoculated with breast carcinoma cells, were injected every 10-12 days with a liposome:p53 complex via the tail vein. A marked reduction of greater than 60% in primary tumor volume was observed. Furthermore, it was found that primary tumor size was not only inhibited but regressed in the majority of p53-treated animals. It was also determined that the administration of the liposome:p53 complex reduced the incidence of metastases in these animals. This is the first report for any cancer that demonstrates the effectiveness of gene therapy systemically delivered that has inhibited the primary tumor and its metastases. In this application one of the goals is to determine the mechanism of action of this therapy. Several hypotheses for the reduction of tumor growth by wild-type p53 will be investigated: 1) activation of the apoptotic pathway, 2) inhibition of the cell cycle, and 3) inhibition of angiogenesis. Whether transfected p53 leads to apoptosis or G1 arrest in tissue culture experiments with endothelial and MDA-MB-435 cells will be examined. Investigation of the number of cells in G1 arrest after harvesting the cells from the primary tumor will also be made. Since increased apoptosis in the p53-treated animals were noted in the first study, examination of tumors for the presence and extent of apoptosis will be undertaken. However, instead of using a liposome:p53 complex which is difficult to detect, either a liposome:CAT or liposome:beta-galactosidase gene will be used to determine the distribution. If the liposome:CAT/beta-galactosidase marker does not transfect the tumor cells efficiently, then this suggests that the liposome:p53 complex is acting through a bystander effect. This bystander effect may be due to inhibition of angiogenesis or the induction of IGF-BP3 by p53. In addition, whether p53 and other genes are more effective than p53 alone will be determined.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
1R29CA070394-01A1
Application #
2009610
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1997-07-15
Project End
2002-06-30
Budget Start
1997-07-15
Budget End
1998-06-30
Support Year
1
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Pathology
Type
Schools of Medicine
DUNS #
003255213
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Leng, Q; Scaria, P; Lu, P et al. (2008) Systemic delivery of HK Raf-1 siRNA polyplexes inhibits MDA-MB-435 xenografts. Cancer Gene Ther 15:485-95
Zhu, Jingsong; Luther, Paul W; Leng, Qixin et al. (2006) Synthetic histidine-rich peptides inhibit Candida species and other fungi in vitro: role of endocytosis and treatment implications. Antimicrob Agents Chemother 50:2797-805
Leng, Qixin; Mixson, A James (2005) Modified branched peptides with a histidine-rich tail enhance in vitro gene transfection. Nucleic Acids Res 33:e40
Zhang, Lei; Leng, Qixin; Mixson, A James (2005) Alteration in the IL-2 signal peptide affects secretion of proteins in vitro and in vivo. J Gene Med 7:354-65
Chen, Qing-Rong; Zhang, Lei; Luther, Paul W et al. (2002) Optimal transfection with the HK polymer depends on its degree of branching and the pH of endocytic vesicles. Nucleic Acids Res 30:1338-45
Zhang, Lei; Gasper, Warren J; Stass, Sanford A et al. (2002) Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res 62:5463-9
Chen, Q R; Zhang, L; Stass, S A et al. (2001) Branched co-polymers of histidine and lysine are efficient carriers of plasmids. Nucleic Acids Res 29:1334-40
Chen, Q R; Zhang, L; Gasper, W et al. (2001) Targeting tumor angiogenesis with gene therapy. Mol Genet Metab 74:120-7
Chen, Q R; Zhang, L; Stass, S A et al. (2000) Co-polymer of histidine and lysine markedly enhances transfection efficiency of liposomes. Gene Ther 7:1698-705
Chen, Q R; Kumar, D; Stass, S A et al. (1999) Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59:3308-12

Showing the most recent 10 out of 12 publications